comparemela.com

Page 15 - Vxrt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Critical Survey: Vaxart (NASDAQ:VXRT) versus Surface Oncology (NASDAQ:SURF)

Vaxart (NASDAQ:VXRT – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends. Risk & Volatility Vaxart has a beta of 0.67, indicating […]

Analysts Anticipate Vaxart, Inc (NASDAQ:VXRT) Will Post Quarterly Sales of $100,000 00

Equities research analysts predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will post sales of $100,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Vaxart’s earnings, with the lowest sales estimate coming in at $90,000.00 and the highest estimate coming in at $100,000.00. Vaxart reported sales of $110,000.00 […]

Vaxart, Inc (NASDAQ:VXRT) Expected to Post Earnings of -$0 20 Per Share

Wall Street brokerages predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will report ($0.20) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vaxart’s earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.22). Vaxart posted earnings per share […]

Vaxart (NASDAQ:VXRT) versus Relay Therapeutics (NASDAQ:RLAY) Critical Contrast

Vaxart (NASDAQ:VXRT – Get Rating) and Relay Therapeutics (NASDAQ:RLAY – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Volatility and Risk Vaxart has a beta of 0.41, indicating that […]

Vaxart (NASDAQ:VXRT) Rating Lowered to Sell at Zacks Investment Research

Vaxart (NASDAQ:VXRT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.